Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
multiple myeloma,refractory multiple myeloma,bortezomib,dexamethasone,final survival outcomes,open-label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要